Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02899702
Other study ID # 69HCL16_0079
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date September 2020
Est. completion date September 2024

Study information

Verified date April 2021
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or staphylococcal toxic shock syndrome in children.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 1 Month to 17 Years
Eligibility Inclusion Criteria: - Child/adolescent: 1 month < Age < 17 year-old, - admitted to PICU with a strong suspicion of staphylococcal or streptococcal infection; at least one following criterion, with at least one following criteria: 1. Toxic Shock Syndrom as defined by Centre for Disease Control criteria 2. or group A Streptococcus necrotizing fasciitis (positive streptest) 3. or varicella with infected lesions and rash or positive streptest 4. or erythrodermic rash in menstrual period 5. or pleuropneumonia with erythrodermic rash or positive streptest in pleural fluid 6. or erythrodermic rash and biological fluid positive to streptococcus A or staphylococcus (articular, pericardial, bronchopulmonary, pharynx) - With shock resistant to fluid resuscitation, defined as existence, despite 40 ml/kg of fluid bolus within 1 hour, of: 1. hypotension (< 5th percentile) 2. or systolic blood pressure < 2 SD regarding age 3. or need for vasoactive drugs in order to maintain blood pressure at a normal level (dopamine > 5µg/kg/min or dobutamine, adrenaline, noradrenaline, milrinone whatever the dose) 4. or 2 signs of hypo perfusion among: 1. metabolic acidosis with base deficit > 5 2. lactate x 2 normal laboratory value 3. diuresis < 0,5 ml/kg/h 4. capillary refill time > 5 sec 5. Skin/central temperature difference > 3°C - With informed consent signed by at least one parent before any procedures or treatments related to the study. Exclusion Criteria: - First signs of shock appeared more than 24h ago - Known hypersensitivity to one of the components (study treatment or placebo , see below) - Hypersensitivity to homologous immunoglobulins, specifically in very rare cases of Ig A deficit, when the patient has anti-IgA antibodies - Known hyperprolinemia - Immunodeficiency (acquired or not), - Immunosuppressive drugs - No health cover

Study Design


Intervention

Drug:
PRIVIGEN (CSL Behring)
Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs). The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.
Albumin
4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality. The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.

Locations

Country Name City State
France Hôpital Femme Mère Enfant Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary organ dysfunctions Average variation in Pediatric Logistic Organ Dysfunction 2 ( PELOD-2) score compared between the IVIG treatment arm and the placebo arm. between day of admission and day 3
Secondary global mortality 1 year
Secondary disability assessed by the Pediatric Overall Performance Category (POPC) score one year after recruitment
Secondary impairment assessed by the Vineland Adaptive Behavior Scale 2 (VABS II) one year after recruitment
Secondary organ dysfunctions assessed by the PELOD-2 score over the first 5 days in Paediatric Intensive Care Unit (PICU)
See also
  Status Clinical Trial Phase
Completed NCT00770341 - A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) Phase 3
Completed NCT00352612 - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Phase 4
Completed NCT00279864 - The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection N/A
Completed NCT00735839 - V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED) Phase 1
Completed NCT00814151 - MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial N/A
Completed NCT02812446 - Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development N/A
Completed NCT00846105 - Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA) N/A
Completed NCT02284555 - Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) Phase 4
Completed NCT01592214 - Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 Phase 1
Completed NCT01827358 - Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants Phase 2
Completed NCT00729937 - Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA" Phase 2/Phase 3
Completed NCT00730028 - Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus Phase 2